Development of 225 Ac Production from Low Isotopic Dilution 229 Th.

The promise of 225 Ac targeted alpha therapies has been on the horizon for the last two decades. TerraPower Isotopes are uniquely suited to produce clinically relevant quantities of 225 Ac through the decay of 229 Th. Herein, a rapid processing scheme to isolate radionuclidic and radioisotopically pure 225 Ac in good yield (98%) produced from 229 Th that contains significant quantities of 228 Th activity is described. The characterization of each step of the process is presented along with the detailed characterization of the resulting 225 Ac isotopic starting material that will support the cancer research and development efforts.